Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreYour world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreFor government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREBalancing the competing priorities of investing in research, services, fundraising, and running an effective organization has long been a challenge for patient organizations. In the COVID-19 era, when incomes have been hit while need for support and services has never been higher, we discuss how patient organization leaders are finding the balance and investing where they can have maximum impact for patient communities, now and in the future. With a particular focus on medical research funding, we also explored how these leaders are prioritizing investment of precious resources in a way that is informed both by the research landscape and patient views.
This paper is informed by a session at the 2022 IQVIA Patient Advocacy Summit which brought together leaders from medical research foundations, networks of research charities, patient foundations and organizations, and IQVIA experts to discuss approaches to prioritizing resource use for maximum impact.
Download this whitepaper to learn more.
Participants
Jennifer Farmer, CEO, Friedreich’s Ataxia Research Alliance (FARA) (USA)
Nicola Perrin, CEO, Association of Medical Research Charities (AMRC) (UK)
Cynthia Rice, Chief Mission Strategy Officer, The Juvenile Diabetes Research Foundation (JDRF) (USA)
Kristin Schneeman, Senior Director, FasterCures, Milken Institute (USA)
Sarah Johnson, Head of Patient Advocacy, EMEA, IQVIA